Department of Genetics, Molecular Immunogenetics Group, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
School of Pharmacy, University of Nottingham, Nottingham, UK.
Adv Exp Med Biol. 2023;1429:13-40. doi: 10.1007/978-3-031-33325-5_2.
Mice have been used in biological research for over a century, and their immense contribution to scientific breakthroughs can be seen across all research disciplines, with some of the main beneficiaries being the fields of medicine and life sciences. Genetically engineered mouse models (GEMMs), along with other model organisms, are fundamentally important research tools frequently utilised to enhance our understanding of pathophysiology and biological mechanisms behind disease. In the 1980s, it became possible to precisely edit the mouse genome to create gene knockout and knock-in mice, although with low efficacy. Recent advances utilising CRISPR-Cas technologies have considerably improved our ability to do this with ease and precision, while also allowing the generation of desired genetic variants from single nucleotide substitutions to large insertions/deletions. It is now quick and relatively easy to genetically edit somatic cells which were previously more recalcitrant to traditional approaches. Further refinements have created a 'CRISPR toolkit' that has expanded the use of CRISPR-Cas beyond gene knock-ins and knockouts. In this chapter, we review some of the latest applications of CRISPR-Cas technologies in GEMMs, including nuclease-dead Cas9 systems for activation or repression of gene expression, base editing and prime editing. We also discuss improvements in Cas9 specificity, targeting efficacy and delivery methods in mice. Throughout, we provide examples wherein CRISPR-Cas technologies have been applied to target clinically relevant genes in preclinical GEMMs, both to generate humanised models and for experimental gene therapy research.
小鼠在生物研究中已经使用了一个多世纪,它们对科学突破的巨大贡献可以在所有研究领域中看到,其中一些主要受益领域是医学和生命科学。基因工程小鼠模型(GEMMs)以及其他模式生物是非常重要的研究工具,经常被用于增强我们对疾病病理生理学和生物学机制的理解。在 20 世纪 80 年代,人们已经可以精确编辑小鼠基因组来创建基因敲除和敲入小鼠,尽管效率较低。最近利用 CRISPR-Cas 技术的进展极大地提高了我们轻松、精确地做到这一点的能力,同时还允许从单核苷酸替换到大片段插入/缺失的所需遗传变体的产生。现在,快速且相对容易地对体细胞进行基因编辑,而体细胞以前更难以采用传统方法进行编辑。进一步的改进创建了一个“CRISPR 工具包”,扩大了 CRISPR-Cas 在基因敲入和敲除之外的应用。在本章中,我们回顾了 CRISPR-Cas 技术在 GEMMs 中的一些最新应用,包括用于基因表达激活或抑制的核酸酶失活 Cas9 系统、碱基编辑和先导编辑。我们还讨论了 Cas9 特异性、靶向效率和在小鼠中的递送方法的改进。在整个过程中,我们提供了 CRISPR-Cas 技术应用于临床相关基因的例子,这些例子在临床前 GEMMs 中既用于生成人源化模型,也用于实验性基因治疗研究。